Abstract: New biocompatible polymeric systems carrying triflusal or HTB are described which result from the polymerization of a monomer A of the acrylic or vinylic type and carrying triflusal or HTB, wherein triflusal or HTB are linked to the remainder of the molecule of said monomer through an in vivo hydrolysable covalent bond, and optionally a second polymerisable monomer B. These new polymeric systems are useful as coating for synthetic biomaterials.

Abstract: New biocompatible polymeric systems carrying triflusal or HTB are described which result from the polymerization of a monomer A of the acrylic or vinylic type and carrying triflusal or HTB, wherein triflusal or HTB are linked to the remainder of the molecule of said monomer through an in vivo hydrolysable covalent bond, and optionally a second polymerisable monomer B. These new polymeric systems are useful as coating for synthetic biomaterials.

Abstract: Compounds of formula I wherein: one of X or Y represents N and the other represents C; R1 represents hydrogen, methyl, halogen, cyano, nitro, —CHO, —COCH3 or —COOR4; PR2 represents optionally-substituted aryl or heteroaryl; R3 represents C1-8 alkyl, C1-8 haloalkyl or —NR4R6; R4 represents hydrogen, C1-8 alkyl or arylC0-8 alkyl; R6 represents hydrogen, C1-8 alkyl, arylC1-8 alkyl, —COR8 or —COOR8; R8 represents C1-8 alkyl or C1-8 haloalkyl; aryl in the above definitions represents phenyl or naphthyl; and heteroaryl in the above definitions represents pyridine, pyrazine, pyrimidine or pyridazine, which can be optionally fused to a benzene ring. These compounds are useful as cyclooxygenase-2 inhibitors.

Abstract: The present invention relates to the sodium salt of (Z)-2-hydroxy-5-([4-[3-[4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl ]-1-piperidinyl]-3-oxo-1-phenyl-1-propenyl]phenyl]azo]benzoic acid, as well as to the pharmaceutical compositions containing it, to a procedure for its preparation and to its use for the manufacture of medicaments for the treatment or prevention of inflammatory bowel disease.

Abstract: Novel imidazole derivatives of formula I and their salts, solvates and prodrugs, wherein the meanings of the different radicals are as shown in the description. Said compounds are useful as anti-inflammatory agents.

Abstract: Process for the preparation of pyrimidone derivatives of formula I, which comprises reacting a compound of formula II with a compound of formula III in the presence of a base. The pyrimidone derivatives of formula I are useful as antifungal agents.

Abstract: The present invention relates to the use of 2-hydroxy or 2-acetyloxy-4-trifluoromethylbenzoic acid, respectively, for the treatment or prevention of mild cognitive impairment (MCI) in mammals, especially in human beings. Futhermore, the present invention also concerns the use of 2-hydroxy or 2-acetyloxy-4-trifluoromethylbenzoic acid, respectively, for delaying or preventing the conversion of MCI into dementia, especially Alzheimer's Disease.

Abstract: Neurodegenerative diseases, such as dementia, including Alzheimer's disease, can be treated or prevented by administering an effective amount of triflusal or its metabolite, or a pharmaceutically acceptable salt or a prodrug thereof.

Abstract: A method for inhibiting the activation of transcription factor NF-&kgr;B in a warm-blooded animal in need thereof, comprises administering to said animal an effective amount of a compound of formula I wherein R represents hydrogen or COCH3, or a pharmaceutically acceptable salt or a prodrug thereof.

Abstract: The invention relates to the use of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-&kgr;B. The invention also relates to the utilization of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives for the preparation of medicaments to treat or prevent of pathologies associated to the activation of NF-&kgr;B and/or the expression of genes which are dependent on or regulated by, at least partially, NF&kgr;B in mammals, including humans.

Abstract: An applicator for semi-solid medications comprises a tubular body (20) having a rounded dispensing end (21) provided with at least one opening (26) and a grasping end (22), the inner surface of a proximal portion of said tubular body defining a reservoir for the medication, a plunger (30), initially housed inside the tubular body, which plunger is provided with a rod (31) and grasping means (33), a piston (40), positioned in sealing contact with the inner surface of said tubular body providing a closure for the medication reservoir, wherein said piston has a longitudinal hole (45) through which rod (31) of the plunger is disposed, and wherein said piston initially abuts on a stop means (25) when the applicator is received by the user, a coupling means (35, 46) between rod (31) and piston (40), a closure means for sealingly closing off said opening (26) on said dispensing end, wherein the plunger (30) is extractable from the tubular body until the rod (31) becomes engaged with the piston (40) by the coupling m

Abstract: Compounds of general formula I and their salts and solvates are antifungal agents and as such are useful in the treatment of various fungal infections. Pharmaceutical compositions including these compounds and processes for their preparation are also provided.

Abstract: Compounds of general formula I and their salts and solvates are angiotensin II receptor antagonists and as such are useful in the treatment of hypertension, congestive heart failure and elevated intraocular pressure. Pharmaceutical compositions including these compounds and processes for their preparation are also provided.

Abstract: The present invention relates to new orally active azole derivatives with antifungal activity of formula I ##STR1## wherein: X is CH or N; Ar represents phenyl substituted with halogen and/or trifluoromethyl; Z is --C(.dbd.O)-- or --SO.sub.2 --; R.sub.1 is CN, CO.sub.2 H, CO.sub.2 R.sub.7, CONR.sub.8 R.sub.9 or CH.sub.2 Y and then R.sub.3 is hydrogen, or R.sub.1 together with R.sub.3 forms a ring of formmula I' ##STR2## wherein B is O, hydroxy or hydrogen; R.sub.4 is C.sub.1-4 alkyl; R.sub.5, R.sub.6, R.sub.8 and R.sub.9 are hydrogen or C.sub.1-4 alkyl; Y is --OH,--OR.sub.7, --OC(.dbd.O)R.sub.7, --NR.sub.8 R.sub.9, --NHC(.dbd.O)OR.sub.7 ; R.sub.7 is C.sub.1 -C.sub.4 -alkyl, phenyl-C.sub.1 -C.sub.4 -alkyl or optionally substituted phenyl; when Z is --C(.dbd.O)--, R.sub.2 is optionally substituted phenyl, or naphtyl; when Z is --SO.sub.2 --, R.sub.2 is C.sub.1-4 alkyl, phenyl-C.sub.1-4 -alkyl or optionally substituted phenyl.

Abstract: Compounds of formula I and their salts and solvates are useful for the treatment or prevention of inflammatory bowel disease. Pharmaceutical compositions including these compounds and processes for their preparation are also provided.

Abstract: Compounds of general formula I and their salts and solvates are PAF antagonists and as such are useful in the treatment of various diseases or disorders mediated by PAF. Pharmaceutical compositions including these compounds and processes for their preparation are also provided.

Abstract: The present invention relates to new orally active azole derivatives with antifungal activity of formula I ##STR1## wherein: X is CH or N; Ar represents phenyl substituted with halogen and/or trifluoromethyl; Z is --C(.dbd.O)-- or --SO.sub.2 --; R.sub.1 is CN, CO.sub.2 H, CO.sub.2 R.sub.7, CONR.sub.8 R.sub.9 or CH.sub.2 Y and then R.sub.3 is hydrogen, or R.sub.1 together with R.sub.3 forms a ring of formula I' ##STR2## wherein B is O, hydroxy or hydrogen; R.sub.4 is C.sub.1-4 alkyl; R.sub.5, R.sub.6, R.sub.8 and R.sub.9 are hydrogen or C.sub.1-4 alkyl; Y is --OH, --OR.sub.7, --OC(.dbd.O)R.sub.7, --NR.sub.8 R.sub.9, --NHC(.dbd.O)OR.sub.7 ; R.sub.7 is C.sub.1 -C.sub.4 -alkyl, phenyl-C.sub.1 -C.sub.4 -alkyl or optionally substituted phenyl; when Z is --C(.dbd.O)--, R.sub.2 is optionally susbtituted phenyl, or naphtyl; when Z is --SO.sub.2 --, R.sub.2 is C.sub.1-4 alkyl, phenyl-C.sub.1-4 -alkyl or optionally susbtituted phenyl.

Abstract: The present invention relates to new imidazopyridine derivatives of formula I ##STR1## wherein: one of A, B, C and D is N and the other are CR, wherein each R independently represents hydrogen, C.sub.1-4 alkyl, COOH or halogen; R.sub.1 represents C.sub.1-4 alkyl or C.sub.3-7 cycloalkyl; Ar.sub.1 represents phenyl or pyridyl which can be optionally substituted; V represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, aryl, aryl-(C.sub.1-4)alkyl or a 5- or 6-membered aromatic heterocycle; the group X-Y represents C.dbd.C or CH--CR.sub.3 ; R.sub.3 represents hydrogen, C.sub.1-4 alkyl or aryl-(C.sub.1-4)alkyl; Z represents among others --CO.sub.2 R.sub.4, --tetrazol-5-yl, --CONHSO.sub.2 R.sub.4, --CONR.sub.4 R.sub.5,--CH.sub.2 NHSO.sub.2 R.sub.4 ; R.sub.4 and R.sub.5 independently represent hydrogen, C.sub.1-4 alkyl, aryl, aryl-(C.sub.1-4)alkyl or perfluoro-(C.sub.1-4)alkyl; W represents hydrogen, cyano, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.3-7 cycloalkyl, aryl, aryl-(C.sub.1-4)alkyl, C.sub.

Abstract: The present invention relates to new orally active azole derivatives with antifungal activity of formula I ##STR1## wherein: X is CH or N; Ar represents phenyl substituted with halogen and/or trifluoromethyl; Z is --C(=O)-- or --SO.sub.2 --; R.sub.1 is CN, CO.sub.2 H, CO.sub.2 R.sub.7, CONR.sub.8 R.sub.9 or CH.sub.2 Y and then R.sub.3 is hydrogen, or R.sub.1 together with R.sub.3 forms a ring of formula I' ##STR2## wherein B is O, hydroxy or hydrogen; R.sub.4 is C.sub.1-4 alkyl; R.sub.5, R.sub.6, R.sub.8 and R.sub.9 are hydrogen or C.sub.1-4 alkyl; Y is --OH, --OR.sub.7, --OC(=O)R.sub.7, --NR.sub.8 R.sub.9, --NHC(=O)OR.sub.7 ; R.sub.7 is C.sub.1 -C.sub.4 -alkyl, phenyl-C.sub.1 -C.sub.4 -alkyl or optionally substituted phenyl; when Z is --C(=O)--, R.sub.2 is optionally susbtituted phenyl, or naphtyl; when Z is --SO.sub.2 --, R.sub.2 is C.sub.1-4 alkyl, phenyl-C.sub.1-4 -alkyl or optionally susbtituted phenyl.

Abstract: The present invention relates to 8-chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidyliden]-6,11-dihydro- 5H-benzo[5,6]cyclohepta[1,2-b]pyridine, to a process for its preparation and to pharmaceutical compositions containing it. This compound is a dual PAF antagonist and antihistamine.